FindTrial
Sign In

Sequential Chemotherapy regimen with vinorelbine and cisplatin plus PET-guided stereotactic ablative radiotherapy (SABR) for castration- and taxane-resistant Prostate cancer (ChemSABR Prostate)

Status
Not yet recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521551-23-01
Enrollment
80
Registered
2025-06-26
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Brief summary

Safety is the primary outcome measure in Phase I of this study, PFS is the primary outcome measure in Phase II.

Interventions

DRUGCISPLATIN
DRUGVINORELBINE

Sponsors

Tartu University Hospital
Lead SponsorOTHER

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Safety is the primary outcome measure in Phase I of this study, PFS is the primary outcome measure in Phase II.—

Countries

Estonia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026